Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.38 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234949 | 1.00 | CASR (0.47) | CASRALDH1A1CYP3A4ACHESYK | |
| SCHEMBL5236993 | 0.83 | ADRB2 (0.52) | CASRALDH1A1CTSAERN1 | |
| SCHEMBL2006306 | 0.83 | ADRB2 (0.52) | CASRALDH1A1CTSAERN1 | |
| SCHEMBL2009918 | 0.83 | CASR (0.49) | CASRSYKBACE1ERN1 | |
| SCHEMBL2009504 | 0.83 | CASR (0.49) | CASRSYKBACE1ERN1 | |
| SCHEMBL14446041 | 0.82 | ACHE (0.58) | ALDH1A1CYP3A4ACHESYKBACE1 | |
| SCHEMBL18084776 | 0.80 | CASR (0.46) | CASRACHECTSAERN1 | |
| SCHEMBL2784662 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP3A4ACHESYKBACE1 | |
| SCHEMBL30913862 | 0.78 | PTPRC (0.50) | CASRPBK | |
| SCHEMBL29225791 | 0.78 | PTPRC (0.50) | CASRPBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | CASR 517/4885ALDH1A1 1050/4885CYP3A4 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.